Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of HS-10383 in Chinese Adult Subjects With Refractory or Unexplained Chronic Cough (RUCC)
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-designed phase 2 clinical trial to evaluate the efficacy, safety and pharmacokinetic (PK) characteristics of HS-10383 in Chinese adult subjects with refractory or unexplained chronic cough (RUCC).
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-designed Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of HS-10383 in Chinese Adult Subjects With Refractory or Unexplained Chronic Cough (RUCC)
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
276
Start Date
2024-03-01
Completion Date
2026-06-01
Last Updated
2024-03-04
Healthy Volunteers
No
Conditions
Interventions
HS-10383
HS-10383 administered as one 50 mg, 100 mg 200 mg tablet once daily, depending upon randomization.
HS-10383 Placebo
HS-10383 administered as one 50 mg, 100 mg 200 mg tablet once daily, depending upon randomization.